Lung Cancer

You are here

Lung Cancer

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Lung Cancer Video Library - Evolving Standards for Molecular Testing in Advanced NSCLC
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer
Lung Cancer Video Library - Combinations of Immunotherapy Agents in Advanced NSCLC: Current Status
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer
Lung Cancer Video Library - The Basics of Managing Immune-Mediated Side Effects
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer
Lung Cancer Video Library - What Should Patients With Rapid Progression Through 1st Line Treatment Receive Next?
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer
Lung Cancer Video Library - "Consolidation" Radiation After a Good Response to First Line Therapy - Who and Why
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer

Articles

Why Carboplatin, Pemetrexed and Pembrolizumab Have Become My New Go-to Regimen for First-Line Non-Squamous NSCLC Treatment
Dr. Jonathan Goldman joins GRACE to explain why carboplatin, pemetrexed and pembrolizumab has become his new go-to regimen for first-line non-squamous NSCLC treatment.
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
My Top 10 ASCO 2017 Lung Cancer Presentations
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Non Small Cell Lung Cancer, Small Cell Lung Cancer
New FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think It's a Poor Choice for Initial Treatment
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Targeted Therapies – ALK
Targeted Therapies Patient Forum September 2017 Speaker Highlight - John Cherol
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce John Cherol, EGFR patient.
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapies Patient Forum September 2017 Speaker Highlight - Sara Whitlock
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce Sara Whitlock, RET + patient.
Cancer Journey:
In Treatment, Survivorship
Cancer Type:
Lung Cancer
Disease Learning:

Community Forum

Adrenal metastasis from NSCLC
Greetings all, I'm a medical doctor from Vietnam. I want to discuss to you about my patient. He is 58 years old, he is hospitalize with chronic...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Lung Cancer, Chemo Medication, Chemotherapy, First-line treatment
Local Therapies for Metastatic Lung Cancer Who, What, Why, When and How?
Hi Grace Members, Grace is happy to present in partnership with the Swedish Cancer Institute " Local Therapies for Metastatic Lung Cancer Who,...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Lung Cancer, Drugs, Targeted Therapies – ALK, Targeted Therapies - EGFR, Targeted Therapies – ROS1, Procedures & Treatments, Chemotherapy, Tumor Marker Tests, Targeted Therapy, Investigational Agents, Immunotherapies, Radiation Therapy, Non Small Cell Lung Cancer
Progression on Tarceva - T790m negative
Progression after 3 1/2 years on Tarceva. Tissue biopsy showed T790m negative. Any suggestions/experience on next steps? Onc suggesting I move to Afatinib or a Opdivo. PDL1 was tested and is <1%.
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Lung Cancer, General Lung Cancer, Targeted Therapies - EGFR, Targeted Therapy, Molecular Testing, Immunotherapies, Non Small Cell Lung Cancer
Keytruda for Adenocarcinoma (NSCLC), first PET-CT result
Hello friends, My mom, (aged 77, Adenocarcinoma NSCLC, Stage 4, EGFR and ALK negative) was diagnosed in 2014, underwent VATS and pleurodesis,...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Lung Cancer, General Lung Cancer, Immunotherapies, Non Small Cell Lung Cancer
Stage IIIb ALK NSCLC first line treatment
This question is not for a specific patient, it is designed to understand how oncologists would approach this problem. There’s a 50 year old stage...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapies – ALK, Non Small Cell Lung Cancer